Azitra Inc (AZTR) AI Stock Analysis

• Market Cap: $2.63M
• Dividend Yield: N/A
• Average Volume (3M): 169.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.04
• Revenue Growth: -100.00%
• EPS Growth: 93.82%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 10,740,697
• 10 Day Avg. Volume: 152,326
• 30 Day Avg. Volume: 169,784
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -0.15
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -5.97
• Enterprise Value/Ebitda: -0.20
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.24 ▼(-20.67% Downside)

The score is primarily held back by weak financial performance: no TTM revenue, large ongoing losses, and significant cash burn despite an improved, low-debt balance sheet. Technicals provide only modest support (short-term improvement but longer-term downtrend), while valuation is constrained by negative earnings and no dividend yield.

Positive Factors

Proprietary microbiome platform

Azitra’s focus on engineered and naturally derived skin microbiome therapeutics establishes a platform-centric business model. A durable platform can generate multiple pipeline assets, create IP barriers and attract partnerships, supporting long-term R&D scalability and differentiated commercial opportunities.

Low leverage and improved equity

Modest debt and materially improved equity reduce near-term solvency and interest burden risks. This balance sheet flexibility supports funding clinical programs or negotiating partnerships without immediate distress, lowering the probability of forced asset sales or urgent dilutive financings over the medium term.

Partnership/collaboration revenue model

A collaboration-driven funding model is structurally beneficial for clinical-stage biotechs: upfronts and milestones can de-risk development, provide non-dilutive or milestone-tied cash infusions, and enable commercialization via partners, improving capital efficiency and strategic optionality over time.

Negative Factors

No recurring commercial revenue

Absence of recurring product revenue means the company depends on financing, collaborations, or one-off receipts to fund operations. Without validated commercial sales, execution risk is higher and future cash flows are uncertain, making long-term self-sufficiency dependent on successful development or partner commercialization.

Sustained cash burn and losses

Consistent large operating losses and negative cash flow erode runway and necessitate further financing or partnerships. Persistent burn increases dilution and constrains strategic choices, potentially slowing program advancement if capital access tightens, posing a durable financing and execution risk.

Listing compliance and delisting risk

Being on a compliance plan creates structural execution risk: failure to meet equity milestones could trigger delisting, impairing access to public capital, reducing liquidity, and harming investor/partner confidence. This timeline-driven regulatory requirement pressures balance sheet actions over months.

Azitra Inc Business Overview & Revenue Model

Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

How the Company Makes Money

Azitra Inc generates revenue through a combination of product sales, licensing agreements, and collaborations with pharmaceutical companies. The primary revenue stream comes from the commercialization of its therapeutic products once they receive regulatory approval. In addition, Azitra may enter into partnerships with larger pharmaceutical companies for co-development and distribution of its products, which can provide upfront payments and milestone payments tied to clinical progress. The company also focuses on securing grants and funding for its research initiatives, which can supplement its income and support ongoing development efforts.

Azitra Inc Financial Statement Overview

Summary

Income statement and cash flow are very weak (TTM revenue $0 with large TTM net loss (~$11.1M) and heavy cash burn; TTM operating cash flow about -$10.9M and TTM free cash flow about -$11.1M). The balance sheet is a relative positive with low leverage (TTM debt-to-equity ~0.22, total debt under $1M) and improved equity vs. prior years, but ongoing losses remain a financing/dilution risk.

Income Statement

Revenue is volatile and not yet sustainable: annual revenue jumped sharply in 2024 ($7.5M vs. $0.686M in 2023), but TTM (Trailing-Twelve-Months) revenue is $0, underscoring uncertainty in recurring commercialization. Profitability remains very weak with persistent large losses (TTM net loss of about $11.1M) and deeply negative margins, reflecting a high cost structure relative to revenue. A positive is that reported gross profit is generally positive in most periods, but operating losses dominate the story.

Balance Sheet

Leverage is modest in the latest periods, with TTM (Trailing-Twelve-Months) debt-to-equity around 0.22 and total debt under $1M, which reduces near-term balance sheet stress. Equity has improved materially versus earlier years (moving from negative equity in 2021–2022 to positive equity in 2023–TTM), indicating prior recapitalization or balance sheet repair. The key weakness is ongoing value destruction: returns on equity are strongly negative in recent periods (TTM return on equity around -5.17), which can pressure the balance sheet over time if losses continue.

Cash Flow

Cash generation is a clear weak point: operating cash flow and free cash flow are consistently negative (TTM operating cash flow about -$10.9M; TTM free cash flow about -$11.1M), signaling continued cash burn typical of early-stage biotech but still a funding risk. Free cash flow also deteriorated versus the prior year (TTM free cash flow growth around -1.205), suggesting burn is not trending down. A relative positive is that free cash flow tracks net loss closely (free cash flow to net income ~1.00–1.06 historically), implying losses are largely reflected in cash outflow rather than being masked by accounting effects.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	7.50M	686.00K	284.00K	110.00K
Gross Profit	-338.37K	7.50M	686.00K	284.00K	110.00K
EBITDA	-10.27M	-8.50M	-10.67M	-10.02M	-8.79M
Net Income	-11.11M	-8.97M	-11.28M	-10.68M	-8.94M
Balance Sheet
Total Assets	4.30M	7.36M	5.12M	7.17M	10.20M
Cash, Cash Equivalents and Short-Term Investments	1.40M	4.55M	1.80M	3.49M	8.04M
Total Debt	795.25K	555.51K	885.95K	7.73M	992.02K
Total Liabilities	2.02M	1.66M	2.20M	43.43M	35.97M
Stockholders Equity	2.28M	5.70M	2.91M	-36.26M	-25.77M
Cash Flow
Free Cash Flow	-11.10M	-10.56M	-7.68M	-8.69M	-8.72M
Operating Cash Flow	-10.92M	-10.18M	-7.36M	-8.35M	-8.07M
Investing Cash Flow	-214.58K	-379.25K	-318.26K	-336.76K	-652.27K
Financing Cash Flow	5.27M	13.32M	5.98M	4.13M	992.86K

Azitra Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.29, below the 50-day MA of 0.31, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.61 is Neutral, neither overbought nor oversold. The STOCH value of 8.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.

Azitra Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AZTR	45 Neutral	$2.63M	-0.04	-215.04%	―	-100.00%	93.82%
INM	44 Neutral	$3.08M	-0.16	-82.17%	―	-3.27%	51.83%
ENVB	42 Neutral	$4.05M	-0.03	-262.78%	―	―	79.45%
ONCO	33 Underperform	$2.21M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.50M	-0.05	-168.95%	―	―	90.27%

Azitra Inc Corporate Events

Azitra Inc Compliance Plan Approved by NYSE American

Azitra, Inc. announced that NYSE American has approved its compliance plan to meet the exchange’s minimum stockholders’ equity requirement by April 1, 2027. While the company’s listing remains active during the plan period, failure to meet milestones or regain compliance by the deadline could lead to delisting proceedings, creating potential implications for operations and investor confidence.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.37 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Azitra Inc Secures $1.5M in Private Placement

On November 24, 2025, Azitra, Inc. entered into a securities purchase agreement with an institutional investor, resulting in a private placement offering of approximately $1.5 million. The offering involved shares of common stock and warrants, with the proceeds intended for general corporate purposes. The agreement includes restrictions on issuing additional shares for 60 days and grants the investor participation rights in future financings. The placement was facilitated by Maxim Group LLC, and the company is required to file a registration statement for the resale of the securities.

The most recent analyst rating on (AZTR) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.